Successful long-term treatment of non-small cell lung cancer positive for
CCDC6-RET
non–small cell lung cancer
pemetrexed
predictive marker
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
04
2019
accepted:
21
06
2019
entrez:
31
7
2019
pubmed:
31
7
2019
medline:
31
7
2019
Statut:
epublish
Résumé
The discovery of
Identifiants
pubmed: 31360064
doi: 10.2147/OTT.S211582
pii: 211582
pmc: PMC6625745
doi:
Types de publication
Case Reports
Langues
eng
Pagination
5355-5358Déclaration de conflit d'intérêts
Dr Masayuki Takeda reports personal fees from Bristol-Myers Squibb, Ono Pharmaceutical Co., Ltd., and Chugai, outside the submitted work. Dr Kazuko Sakai received lecture fees from Roche Diagnostics, Bio-Rad Laboratories, SRL, AstraZeneca, Thermo Fisher Scientific, and Becton, Dickinson and Company, outside the submitted work. Professor Kazuto Nishio reports grants from Korea Otsuka Pharmaceutical Co., Ltd., Life Technologies Japan Ltd., Astellas Pharma Inc., Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd., and Ignyta, Inc., and received lecture fees from Sumitomo Bakelite Co., Ltd., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca K.K., Eisai Co., Ltd., MSD K.K., Otsuka Pharmaceutical, Sanofi, Solasia Pharma, Taiho Pharmaceutical Co. Ltd, Eli Lilly Japan K.K., Pfizer Inc., Bristol Myers Squibb, Life Technologies Japan Ltd., Novartis Japan, and SymBio Pharmaceuticals, outside the submitted work. Professor Kazuhiko Nakagawa reports grants and personal fees from MSD K.K., Eli Lilly Japan K.K., Bristol Myers Squibb Company, Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Merck Serono Co., Ltd., AstraZeneca K.K., Astellas Pharma Inc., Novartis Pharma K.K., Nippon Boehringer Ingelheim Co., Ltd., and Pfizer Japan Inc., during the conduct of the study. He also received grants and personal fees from CON Japan K.K., Takeda Pharmaceutical Co., Ltd., PAREXEL International Corp., IQVIA Services Japan K.K., A2 Healthcare Corp., AbbVie Inc., SymBio Pharmaceuticals Limited., EP-CRSU Co. Ltd., Linical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., EPS International Co., Ltd., Quintiles Inc., CMIC Shift Zero K.K., Eisai Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd, EPS Corporation., Daiichi Sankyo Co., Ltd., Bayer Yakuhin Ltd, inVentiv Health Japan, Gritsone Oncology Inc, GlaxoSmithKline K.K., Yakult Honsha Co., Ltd., Covance Inc., Kyorin Pharmaceutical Co., Ltd., CareNet, Inc, Nichi-Iko Pharmaceutical Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Nikkei Business Publications, Inc., Thermo Fisher Scientific K.K., Nanzando Co., Ltd, Medical Review Co., Ltd., Yomiuri Telecasting Corp., and Reno Medical K.K., outside the submitted work. The authors report no other conflicts of interest in this work.
Références
J Thorac Oncol. 2011 Apr;6(4):774-80
pubmed: 21336183
Br J Cancer. 2011 May 10;104(10):1594-601
pubmed: 21487406
Clin Lung Cancer. 2012 Mar;13(2):157-9
pubmed: 22056890
Nat Med. 2012 Feb 12;18(3):378-81
pubmed: 22327623
Nat Med. 2012 Feb 12;18(3):375-7
pubmed: 22327624
Cancer Discov. 2013 Jun;3(6):630-5
pubmed: 23533264
N Engl J Med. 2013 Jun 20;368(25):2385-94
pubmed: 23724913
Ann Oncol. 2015 Dec;26(12):2477-82
pubmed: 26420428
Ann Oncol. 2016 Jul;27(7):1286-91
pubmed: 27056998
J Thorac Oncol. 2016 Nov;11(11):2027-2032
pubmed: 27544060